by Ethan A. Huff
Having to wait two months after birth to administer the first round of vaccines to an infant (with the exception of the fraudulent Hepatitis B vaccine) is apparently too long for the money-hungry vaccine industry, which is hard at work on a new vaccine technology that will allow vaccines to be administered immediately after a child is born.
According to a new study
published in the open-access journal PLoS ONE, scientists have
already concocted a synthetic substance they say is capable of
effectively triggering an immune response in newborn babies, a fresh
feat for the industry.
But as reported by
Boston Children's Hospital, a team of scientists from the
Massachusetts-based health facility, and led by Dr. Ofer Levy,
M.D., Ph.D., has discovered a synthetic molecular component that
reportedly triggers an immune response in undeveloped immune
TLR 8 samples taken from
newborn cord blood revealed that benzazepines can target certain
white blood cells and trigger an immune response similar to what
would occur in an older child or in an adult given a vaccine.
Based on their findings,
researchers concluded that VTX-294 is at least 10 times more
effective at stimulating TLR 8 than any other known substance, which
makes it a viable candidate for insertion into future vaccines.
And as soon as the
benzazepine class of chemicals is approved for commercial use, you
can expect doctors and nurses at hospitals and healthcare facilities
to begin pressuring parents of newborns to have their children
vaccinated immediately after birth, when their immune systems have
had no time whatsoever to develop naturally.
After all, the first few
months of a child's life are crucial for this important stage of
immune development, and injecting them with chemical-laden vaccines
the minute they are delivered into the world only obstructs this